Vitiligo

Incyte representative Todd Edwards discusses how the awards help address challenges faced by patients with vitiligo.

As we have surpassed the halfway mark of 2023, Dermatology Times is spotlighting vitiligo coverage and news from the first half of year.

The authorization comes just over 2 months after the drug’s approval in the European Union.

Trained immunity may act as an enhancer and continuous trigger in the disease’s pathogenesis.

The combination of therapies achieved significant efficacy, with researchers noting a higher cure rate than is evident in other therapies for the condition.

In recognition of World Vitiligo Day, the Dermatology Times team is spotlighting advances and educational opportunities for the condition.

Despite this, researchers found that Hsp70 plasma levels did not correlate with the extent of disease.

Investigators compared data among patients with vitiligo and the general population.

More research is needed to specify long-term efficacy of the treatment and its ideal dose.

Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.

Hamzavi spoke at the 2023 Pigmentary Disorder Exchange Symposium in Chicago.

The pigment disorder is associated with several autoimmune and systemic comorbidities.

Researchers compared counts between patients with vitiligo and a control group of patients.

Researchers have identified what may be the first report of vitiligo induced de novo by dupilumab therapy.

Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.

Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.

Researchers said laser and intense pulse light-induced vitiligo lacks consensus in prevention and safety measures.

According to new research, vitamin D and serum brain-derived neurotrophic factors may exacerbate depression in some dermatologic patients.

The investigational oral JAK1 inhibitor showed promising results for vitiligo patients.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

Following 2 phase 3 trials, the European Medicines Agency Committee for Medicinal Products for Human Use gives positive opinion on the use of ruxolitinib cream as a treatment for facial-involved non-segmental vitiligo.

Research has begun to explore natural compounds that address the oxidative stress, autoimmunity, and altered melanogenesis that drive vitiligo pathogenesis.

Latin America presents a patchwork of challenges and opportunities in vitiligo management according to a review published in the Journal of Dermatological Treatment.

Clinicians should strive to address the unique medical and aesthetic challenges seen in vitiligo.

PDT has an advantage in that it can combine easily with other therapies, thereby increasing its effectiveness rates.